Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intomics and LEO Pharma have entered into a collaboration under which LEO Pharma will gain access to Intomics’ biological data analysis expertises. Intomics, the recently founded spin-off company from The Danish Technical University, has methods and tools for use in LEO Pharma’s early drug discovery.
Subscribe to our email newsletter
Reportedly, the collaboration spans a range of research projects.
Thomas Jensen, founder and CEO of Intomics, said: “We are extremely pleased to be working with LEO Pharma on their discovery projects. Using our unique expertise and biological data analysis technologies, we can facilitate fast, efficient research projects with improved results for LEO Pharma.
“Today, research projects generate large amounts of biological data, and sophisticated analyses of these are required to optimise the success rate of research projects. To facilitate this, both highly specialised know how and advanced tools are required.
“The synergy between LEO Pharma’s research in dermatology and critical care, and Intomics’ expertise in advanced biological analyses, will help face this challenge and lead to better, safer drugs – and ultimately benefit patients in these important areas.”